O'Donnell-Tormey Jill 4
4 · Coherus Oncology, Inc. · Filed Jun 9, 2026
Research Summary
AI-generated summary of this filing
Coherus (CHRS) Director Jill O'Donnell-Tormey Receives Awards
What Happened
Jill O'Donnell-Tormey, a director of Coherus Oncology (CHRS), received equity awards on 2026-06-05: 30,000 restricted stock units (RSUs) and a 60,000-share derivative award (grant reported at $0.00, i.e., no cash paid). These are grants (not open‑market purchases or sales) and are typically part of director compensation.
Key Details
- Transaction date: June 5, 2026; Form 4 filed June 9, 2026 (filed within the required two business days).
- Consideration: $0.00 per share (award/grant). Reported amounts: 30,000 (RSUs) + 60,000 (derivative award).
- Shares owned after transaction: not specified in the provided filing excerpt.
- Footnotes:
- F1 (30,000 RSUs): Each RSU converts to one share; 100% vest on the one‑year anniversary of June 3, 2026 (i.e., June 3, 2027), subject to continued service.
- F2 (60,000 derivative award): Underlying shares vest and become exercisable 100% on June 3, 2027, subject to continued service.
- Transaction code: A = Award/Grant.
Context
RSUs and derivative awards are common forms of director compensation and do not involve an immediate cash outlay or market sale. The derivative award appears to be an option-like grant that will become exercisable when it vests. These grants reflect compensation timing and vesting conditions rather than an expressed buy/sell sentiment.
Insider Transaction Report
- Award
Common Stock
[F1]2026-06-05+30,000→ 30,000 total - Award
Stock Option (Right to Buy)
[F2]2026-06-05+60,000→ 60,000 totalExercise: $1.45Exp: 2036-06-05→ Common Stock (60,000 underlying)
Footnotes (2)
- [F1]Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
- [F2]The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.